Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France

Medecine et Maladies Infectieuses

Volumn 39, Issue 5, 2009, Pages 330-340

  De Cock, E ^a   Sorensen, S ^b   Levrat, F ^c   Besnier, J M ^d   Dupon, M ^e   Guery, B ^f   Duttagupta, S ^c  

^a United BioSource Corporation   (Spain)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c PFIZER INC   (United States)

^d CHU BRETONNEAU   (France)

^e HÔPITAL PELLEGRIN   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Complicated skin and soft tissue infection; Cost effectiveness; Linezolid; MRSA; Vancomycin

Indexed keywords

CLINDAMYCIN; IMIPENEM; LINEZOLID; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; VANCOMYCIN;

ANEMIA; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG WITHDRAWAL; FEVER; FRANCE; HOSPITALIZATION; HUMAN; INFECTION COMPLICATION; KIDNEY FAILURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRESCRIPTION; SKIN INFECTION; SOFT TISSUE INFECTION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ACETAMIDES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DECISION TREES; DRUG MONITORING; FRANCE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INPATIENTS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 67349217377     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2009.01.005     Document Type: Article

References (38)

1. Dykhuizen R.S., Trent R.J., Pacitti D.P., Reid T.M., Douglas J.G., and Smith C.C. An analysis of 900 consecutive admissions to a regional infection unit. J Infect 29 (1994) 189-193
2. Nathwani D., Moitra S., Dunbar J., Crosby G., Peterkin G., and Davey P. Skin and soft-tissue infections: development of a collaborative management plan between community and hospital care. Int J Clin Pract 52 (1998) 456-460
3. Tice A.D., Poretz D., Cook F., Zinner D., and Strauss M.J. Medicare coverage of outpatient ambulatory intravenous antibiotic therapy: a program that pays for itself. Clin Infect Dis 27 (1998) 1415-1421
4. Swartz M.N. Cellulitis and superficial infections. In: Mandell G., Douglas R., and Bennett J. (Eds). Principles and Practice of Infectious Diseases-1990 (1992), Churchill Livingstone, New York 796-807
5. Lee S.Y., Kuti J.L., and Nicolau D.P. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 6 (2005) 283-295
6. Jones M.E., Karlowsky J.A., Draghi D.C., Thornsberry C., Sahm D.F., and Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft-tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 22 (2003) 406-419
7. EARSS. EARSS Annual Report. Bilthoven, Netherlands. October 2006.
8. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., and Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36 (2003) 53-59
9. Lodise T.P., and McKinnon P.S. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 52 (2005) 113-122
10. Reed S.D., Friedman J.Y., Engemann J.J., et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 26 (2005) 175-183
11. CDC. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States. MMWR 1997;46:813-5.
12. Ploy M.C., Grelaud C., Martin C., de Lumley L., and Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351 (1998) 1212
13. Wong S.S., Ho P.L., Woo P.C., and Yuen K.Y. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 29 (1999) 760-767
14. Swaney S.M., Aoki H., Ganoza M.C., and Shinabarger D.L. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 42 (1998) 3251-3255
15. Zurenko G.E., Yagi B.H., Schaadt R.D., et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 40 (1996) 839-845
16. Yaldo A.Z., Sullivan J.L., and Li Z. Factors influencing physicians' decision to discharge hospitalized patients infected with methicillin-resistant Staphylococcus aureus. Am J Health Syst Pharm 58 (2001) 1756-1759
17. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., and Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft-tissue infections. Antimicrob Agents Chemother 49 (2005) 2260-2266
18. Itani K.M., Weigelt J., Li J.Z., and Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft-tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 26 (2005) 442-448
19. McKinnon P.S., Sorensen S.V., Liu L.Z., and Itani K.M. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 40 (2006) 1017-1023
20. Vinken A., Li Z., Balan D., Rittenhouse B., Wilike R., and Nathwani D. Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model. J Hosp Infect 49 (2001) S13-S24
21. Vinken A.G., Li J.Z., Balan D.A., Rittenhouse B.E., Willke R.J., and Goodman C. Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals. Am J Ther 10 (2003) 264-274
22. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., and Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34 (2002) 1481-1490
23. Weigelt J., Kaafarani H.M., Itani K.M., and Swanson R.N. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 188 (2004) 760-766
24. Stevens D.L., Smith L.G., Bruss J.B., et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft-tissue infections. Antimicrob Agents Chemother 44 (2000) 3408-3413
25. Assurance maladie. Tarifs conventionnels des médecins généralistes. Available at: http://www.ameli.fr/professionnels-de-sante/medecins/votre-convention/ta rifs. Accessed July 20, 2006.
26. Assurance maladie. Tarifs conventionnels des médecins spécialistes. Available at: http://www.ameli.fr/professionnels-de-sante/medecins/votre-convention/ta rifs. Accessed July 20, 2006.
27. Assurance maladie. Tarifs conventionnels des infirmiers. Available at: http://www.ameli.fr/professionnels-de-sante/infirmiers/votre-convention/ les-tarifs-conventionnels.php. Accessed July 20, 2006.
28. Caisse nationale de l'Assurance maladie. Nomenclature des actes de biologie médicale (NABM): version 5 juillet 2006.
29. Caisse nationale de l'Assurance maladie des travailleurs salariés. Nomenclature générale des actes professionnels médecins, chirurgiens-dentistes, sages-femmes et auxiliaires médicaux (NGAP): 17 janvier 2005.
30. Échelle nationale de coûts par GHM (données 2003-2004). Available at: http://www.atih.sante.fr/?id=000370000AFF. Accessed July 20, 2006.
31. Comptabilité analytique de l'Assistance Publique-Hôpitaux de Paris (AP-HP). Paris; 2000.
32. Agence technique de l'information sur l'hospitalisation. Programme de médicalisation des systèmes d'information (PMSI); 2005.
33. Wernitz M.H., Keck S., Swidsinski S., Schulz S., and Veit S.K. Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clin Microbiol Infect 11 (2005) 466-471
34. Popp W., Hilgenhoner M., Leisebein T., and Muller H. Personalkosten durch Isolierungsmassnahmen von MRSA-Patienten. Gesundh Okon Qual Manag 8 (2003) 187-190
35. Li Z., Willke R.J., Pinto L.A., et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 21 (2001) 263-274
36. Plosker G.L., and Figgitt D.P. Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections. Pharmacoeconomics 23 (2005) 945-964
37. Vidal. Available at: www.vidalpro.net. Accessed July 20, 2006.
38. Caisse nationale de l'Assurance maladie des travailleurs salariés. Classification commune des actes médicaux (CCAM): version 4 applicable au 17 mai 2006.